325 related articles for article (PubMed ID: 10232596)
1. Paracrine immunotherapy with interleukin-2 and local chemotherapy is synergistic in the treatment of experimental brain tumors.
Sampath P; Hanes J; DiMeco F; Tyler BM; Brat D; Pardoll DM; Brem H
Cancer Res; 1999 May; 59(9):2107-14. PubMed ID: 10232596
[TBL] [Abstract][Full Text] [Related]
2. Local delivery of chemotherapy and concurrent external beam radiotherapy prolongs survival in metastatic brain tumor models.
Ewend MG; Williams JA; Tabassi K; Tyler BM; Babel KM; Anderson RC; Pinn ML; Brat DJ; Brem H
Cancer Res; 1996 Nov; 56(22):5217-23. PubMed ID: 8912860
[TBL] [Abstract][Full Text] [Related]
3. Injection of chemotherapeutic microspheres and glioma. IV: Eradicating tumors in rats.
Emerich DF; Winn SR; Bartus RT
Cell Transplant; 2002; 11(1):47-54. PubMed ID: 12095219
[TBL] [Abstract][Full Text] [Related]
4. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
O'Malley BW; Li D; McQuone SJ; Ralston R
Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
[TBL] [Abstract][Full Text] [Related]
5. Implantable polymers for tirapazamine treatments of experimental intracranial malignant glioma.
Yuan X; Tabassi K; Williams JA
Radiat Oncol Investig; 1999; 7(4):218-30. PubMed ID: 10492162
[TBL] [Abstract][Full Text] [Related]
6. Local immunotherapy with interleukin-2 delivered from biodegradable polymer microspheres combined with interstitial chemotherapy: a novel treatment for experimental malignant glioma.
Rhines LD; Sampath P; DiMeco F; Lawson HC; Tyler BM; Hanes J; Olivi A; Brem H
Neurosurgery; 2003 Apr; 52(4):872-9; discussion 879-80. PubMed ID: 12657184
[TBL] [Abstract][Full Text] [Related]
7. Local IL-4 delivery enhances immune reactivity to murine tumors: gene therapy in combination with IL-2.
Pippin BA; Rosenstein M; Jacob WF; Chiang Y; Lotze MT
Cancer Gene Ther; 1994 Mar; 1(1):35-42. PubMed ID: 7621236
[TBL] [Abstract][Full Text] [Related]
8. A safety and efficacy study of local delivery of interleukin-12 transgene by PPC polymer in a model of experimental glioma.
Sonabend AM; Velicu S; Ulasov IV; Han Y; Tyler B; Brem H; Matar MM; Fewell JG; Anwer K; Lesniak MS
Anticancer Drugs; 2008 Feb; 19(2):133-42. PubMed ID: 18176109
[TBL] [Abstract][Full Text] [Related]
9. Antitumor effect of interleukin 7 in combination with local hyperthermia in mice bearing B16a melanoma cells.
Wu B; Shen RN; Wang WX; Broxmeyer HE; Lu L
Stem Cells; 1993 Sep; 11(5):412-21. PubMed ID: 8241952
[TBL] [Abstract][Full Text] [Related]
10. Synergistic effects of combination therapy with human recombinant interleukin-2 and tumor necrosis factor in murine tumor models.
Winkelhake JL; Stampfl S; Zimmerman RJ
Cancer Res; 1987 Aug; 47(15):3948-53. PubMed ID: 3496953
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of combined interleukin 2 and B7.1 vaccination strategy is dependent on the sequence and order: a liposome-mediated gene therapy treatment for bladder cancer.
Larchian WA; Horiguchi Y; Nair SK; Fair WR; Heston WD; Gilboa E
Clin Cancer Res; 2000 Jul; 6(7):2913-20. PubMed ID: 10914741
[TBL] [Abstract][Full Text] [Related]
12. The role of BCNU polymer wafers (Gliadel) in the treatment of malignant glioma.
Nagpal S
Neurosurg Clin N Am; 2012 Apr; 23(2):289-95, ix. PubMed ID: 22440872
[TBL] [Abstract][Full Text] [Related]
13. Chemoimmunotherapy in mice carrying HPV16-associated, MHC class I+ and class I- tumours: Effects of CBM-4A potentiated with IL-2, IL-12, GM-CSF and genetically modified tumour vaccines.
Indrová M; Bubeník J; Mikysková R; Mendoza L; Símová J; Bieblová J; Jandlová T; Jinoch P; Smahel M; Vonka V; Pajtasz-Piasecka E
Int J Oncol; 2003 Mar; 22(3):691-5. PubMed ID: 12579325
[TBL] [Abstract][Full Text] [Related]
14. Optimizing interstitial delivery of BCNU from controlled release polymers for the treatment of brain tumors.
Sipos EP; Tyler B; Piantadosi S; Burger PC; Brem H
Cancer Chemother Pharmacol; 1997; 39(5):383-9. PubMed ID: 9054951
[TBL] [Abstract][Full Text] [Related]
15. Induction of antitumor immunity by combined immunogene therapy using IL-2 and IL-12 in low antigenic Lewis lung carcinoma.
Tanaka M; Saijo Y; Sato G; Suzuki T; Tazawa R; Satoh K; Nukiwa T
Cancer Gene Ther; 2000 Nov; 7(11):1481-90. PubMed ID: 11129290
[TBL] [Abstract][Full Text] [Related]
16. Granulocyte-macrophage colony-stimulating factor and interleukin-2 fusion cDNA for cancer gene immunotherapy.
Stagg J; Wu JH; Bouganim N; Galipeau J
Cancer Res; 2004 Dec; 64(24):8795-9. PubMed ID: 15604233
[TBL] [Abstract][Full Text] [Related]
17. Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha.
Halin C; Gafner V; Villani ME; Borsi L; Berndt A; Kosmehl H; Zardi L; Neri D
Cancer Res; 2003 Jun; 63(12):3202-10. PubMed ID: 12810649
[TBL] [Abstract][Full Text] [Related]
18. Chemoimmunotherapy for melanoma with dacarbazine and 2,4-dinitrochlorobenzene elicits a specific T cell-dependent immune response.
Wack C; Kirst A; Becker JC; Lutz WK; Bröcker EB; Fischer WH
Cancer Immunol Immunother; 2002 Oct; 51(8):431-9. PubMed ID: 12202904
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic effect of colon tumor cells expressing FLT-3 ligand plus systemic IL-2 in mice with syngeneic colon cancer.
Sivanandham M; Stavropoulos CI; Kim EM; Mancke B; Wallack MK
Cancer Immunol Immunother; 2002 Apr; 51(2):63-71. PubMed ID: 11904730
[TBL] [Abstract][Full Text] [Related]
20. Cancer immunotherapy of established tumors with IL-12. Effective delivery by genetically engineered fibroblasts.
Zitvogel L; Tahara H; Robbins PD; Storkus WJ; Clarke MR; Nalesnik MA; Lotze MT
J Immunol; 1995 Aug; 155(3):1393-403. PubMed ID: 7636204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
